Objective: To prepare an anti-HIV combination drug containing three APIs, and evaluate the in-vitro dissolution profile and in-vivo pharmacokinetics in beagle dogs.Methods: The anti-HIV combination drug was prepared by a parallel granulating technique.The dissolution was assayed by HPLC and the similarity of dissolution profiles was compared between the combination product and mixed single-API tablets.Beagle dogs were given the combination and mixed single-API tablets in a two-phase crossover study.The plasma concentrations of lamivudine, tenofovir disoproxil fumarate and ACC007 were assayed by HPLC-MS, and the pharmacokinetic parameters were compared between the combination and mixed single-API tablets.Results: The similarity factors f_2 of the three APIs in four kinds of media were all more than 50, and there was no difference in the main pharmacokinetic parameters of the three APIs in beagle dogs between the combination and mixed single-API tablets.Compared with mixed single-API tablets, the average relative bioavailability of lamivudine, tenofovir disoproxil fumarate and ACC007 in the combination drug was 108%, 91% and 112% resp.Conclusion: The dissolution behaviors are similar and bioavailabilities are equivalent in beagle dogs between the combination and mixed single-API tablets, suggesting that the two products are probably clin. equivalent